Home › Employers › Hememics Biotechnologies, Inc.
Hememics Biotechnologies, Inc.: H-1B salaries and sponsorship
Hememics Biotechnologies, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $73,694.
Does Hememics Biotechnologies, Inc. sponsor H-1B visas?
Hememics Biotechnologies, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Aug 11, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Data Analyst | 2 | $80,000 |
| Scientist II | 1 | $73,694 |
| Research Scientist | 1 | $73,694 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 1 | $73,694 |
| FY2025 | 3 | $73,694 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Data Analyst | $88,000 Level I | Gaithersburg, MD | Aug 11, 2025 | Oct 1, 2025 | Certified |
| Research Scientist | $73,694 Level I | Gaithersburg, MD | May 2, 2025 | Oct 1, 2025 | Certified |
| Data Analyst | $72,000 Level I | Gaithersburg, MD | Apr 22, 2025 | Oct 1, 2025 | Certified |
| Scientist II | $73,694 Level I | Gaithersburg, MD | Jun 4, 2024 | Oct 1, 2024 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).